Finance

Beta
Lists
AVTX:NASDAQ
Avalo Therapeutics Inc
$18.48
-4.20%
(-0.81) 1D
$18.48
0.00% (0.00)
After hours
Closed: Jun 30, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AVTX...
Open
$19.45
High
$20.10
Low
$18.29
Mkt. cap
971.41M
Avg. vol.
1.89M
Volume
60.00
52-wk high
$24.27
52-wk low
$4.61
EPS
-$5.83
Beta
0.83
Shares outstanding
52.57M
No. of employees
33
Open
$19.45
High
$20.10
Low
$18.29
Mkt. cap
971.41M
Avg. vol.
1.89M
Volume
60.00
52-wk high
$24.27
52-wk low
$4.61
EPS
-$5.83
Beta
0.83
Shares outstanding
52.57M
No. of employees
33
News stories
From sources across the web
About Avalo Therapeutics Inc
CEO-
Employees33
Founded2011
HeadquartersRockville, Pennsylvania, United States
SectorBiotechnology
Websiteavalotx.com
Analyst ratings
Based on 11 analysts giving stock ratings to AVTX in the past 3 months
Strong buy
Buy
11
Hold
0
Sell
0
12-month forecast
Based on 11 Wall Street analysts offering 12 month price targets for AVTX in the last 3 months.
Highest
Current $18.48
$60.00 (+224.68%)
Average
$45.90 (+148.38%)
Lowest
$34.00 (+83.98%)
Analyst
Recommendation
Action
Price target
Projected
Date
Alec Stranahan
Bank of America Securities
Buy
Initiated
$35.00
+89.4%
06/12/2026
Stacy Ku
TD Cowen
Buy
Maintained
-
-
06/11/2026
Alex Thompson CFA
Stifel Nicolaus
Buy
Maintained
$39.00
+111%
05/15/2026
Robert Driscoll
Wedbush
Buy
Reiterated
$34.00
+84%
05/14/2026
Joseph Catanzaro
Mizuho Securities
Buy
Maintained
$45.00
+143.5%
05/14/2026
Mitchell Kapoor
H.C. Wainwright
Buy
Reiterated
$35.00
+89.4%
05/14/2026
Julian Harrison
BTIG
Buy
Maintained
$58.00
+213.9%
05/13/2026
Jason Butler
Citizens JMP
Buy
Maintained
$55.00
+197.6%
05/14/2026
Yasmeen Rahimi
Piper Sandler
Buy
Reiterated
$60.00
+224.7%
05/11/2026
Yatin Suneja
Guggenheim
Buy
Maintained
$50.00
+170.6%
05/06/2026
Andy Chen
Wolfe Research
Buy
Initiated
$48.00
+159.7%
04/08/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
59.00K
-
Cost of goods sold
10.66M
9.99M
8.78M
10.15M
Cost of revenue
10.66M
9.99M
8.78M
10.15M
Research and development expenses
3.41M
3.63M
4.48M
3.90M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.24M
5.58M
6.53M
6.85M
Operating expense
8.66M
9.21M
11.02M
10.75M
Total operating expenses
19.32M
19.20M
19.80M
20.90M
Operating income
-19.32M
-19.20M
-19.74M
-20.90M
Other non operating income
-2.54M
-12.53M
5.17M
480.00K
EBT including unusual items
-20.75M
-30.61M
-13.59M
-19.62M
EBT excluding unusual items
-20.75M
-30.61M
-13.59M
-19.62M
Income tax expense
16.00K
11.00K
130.00K
12.00K
Effective tax rate
-0.08%
-0.04%
-0.96%
-0.06%
Other operating expenses
-
-
-
-
Net income
-20.76M
-30.62M
-13.72M
-19.63M
Net profit margin
-
-
-23,254.24%
-
Earnings per share
-1.92
-2.19
-0.37
-0.98
Interest and investment income
1.10M
1.12M
984.00K
803.00K
Interest expense
-
-
-
-
Net interest expenses
1.10M
1.12M
984.00K
803.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-19.18M
-19.14M
-19.73M
-20.88M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer